Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A uniform tissue-clearing framework and mesoSPIM-ultra enable cm-scale single-neuron tracing.

bioRxiv : the preprint server for biology·2026
Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026
Same author

Statescope: an integrative deconvolution framework for discovering cell states in tumors.

Nature communications·2026
Same author

Co-option and innovation in neural crest evolution.

Science advances·2026
Same author

Cortical development dynamics across autism spectrum disorder mouse models.

Nature·2026
Same author

C1q-targeting bispecific antibodies bypass Fc to trigger complement activation and receptor clustering agonism.

Molecular immunology·2026

Related Experiment Video

Updated: Oct 11, 2025

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.5K

Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors.

Ellen M Westerhout1, Mohamed Hamdi2, Peter Stroeken2

  • 1Department of Oncogenomics, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. e.m.westerhout@amsterdamumc.nl r.versteeg@amsterdamumc.nl.

Cancer Research
|December 2, 2021
PubMed
Summary

Immature mesenchymal (MES) neuroblastoma cells resist anaplastic lymphoma kinase inhibitors (ALKi). Combining ALKi with TRAIL therapy effectively targets MES cells and delays neuroblastoma relapse.

More Related Videos

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.3K
Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

11.4K

Related Experiment Videos

Last Updated: Oct 11, 2025

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.5K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.3K
Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

11.4K

Area of Science:

  • Oncology
  • Developmental Biology
  • Cancer Therapeutics

Background:

  • Cancer therapy resistance is a major clinical challenge, often linked to immature tumor cell populations.
  • Neuroblastoma cells exhibit plasticity, differentiating into adrenergic (ADRN) or immature mesenchymal (MES) states.
  • MES cells display increased resistance to chemotherapy and harbor distinct epigenetic and transcriptional profiles compared to ADRN cells.

Purpose of the Study:

  • To investigate the response of immature mesenchymal (MES) neuroblastoma cells to targeted therapies, specifically anaplastic lymphoma kinase inhibitors (ALKi).
  • To evaluate the role of MES cells in neuroblastoma relapse and assess potential therapeutic strategies targeting these cells.
  • To understand the intrinsic mechanisms of drug resistance in immature cancer cells.

Main Methods:

  • Analysis of MES cell response to targeted drugs, including ALKi.
  • Assessment of anaplastic lymphoma kinase (ALK) expression in both ADRN and MES neuroblastoma cells.
  • In vivo studies using neuroblastoma xenografts treated with ALKi, TRAIL, or combination therapy to evaluate tumor progression and relapse dynamics.

Main Results:

  • MES neuroblastoma cells lack both wild-type and mutant anaplastic lymphoma kinase (ALK) expression, rendering them resistant to ALKi.
  • MES cells formed tumors that progressed under ALKi treatment, highlighting their role in therapeutic failure.
  • TRAIL specifically induced apoptosis in MES cells and suppressed their tumor growth.
  • Combination therapy with ALKi and TRAIL delayed relapse in a subset of neuroblastoma xenograft models.

Conclusions:

  • Therapeutic resistance in neuroblastoma can be an intrinsic property of immature MES cells due to their lack of targetable oncogenes like ALK.
  • Targeting MES cells with agents like TRAIL, in combination with ALKi, offers a promising strategy to overcome resistance and delay tumor relapse.
  • The resemblance of MES cells to developmental precursor cells may explain their inherent resistance to targeted therapies.